Cfhr4, a complement factor H-related 4 protein, plays a crucial role in the regulation of complement activation, acting as a multifaceted mediator in the intricate immune defense system. Functionally, Cfhr4 is characterized by its ability to bind complement component C3b and heparin, positioning it within the extracellular space where it exerts its influence on the complement cascade. The interaction with C3b and heparin binding sites indicates Cfhr4's involvement in both the initiation and regulation of complement activation, a process vital for immune responses against pathogens and maintenance of homeostasis. The activation mechanisms of Cfhr4 involve a nuanced interplay of compounds designed to directly target its functional domains. Activation of the C3b binding site is envisioned through a compound that mimics the physiological ligand, promoting direct interaction with Cfhr4 and triggering the initiation of complement activation. Simultaneously, an idealized compound acting as a heparin activator influences Cfhr4 by directly binding to its heparin-binding site, augmenting the protein's regulatory role in the extracellular environment. These direct activators showcase a potential strategy to modulate Cfhr4's engagement with C3b and heparin, fine-tuning its involvement in complement activation processes.
Furthermore, the envisioned activators targeting specific signaling pathways such as NF-κB, PI3K/Akt, SIRT1, MAPK, and Nrf2 propose an alternative avenue for Cfhr4 activation. Activation through these pathways suggests a more intricate and comprehensive regulatory role for Cfhr4 in modulating the immune response. These proposed mechanisms of activation provide a conceptual framework for understanding the functional dynamics of Cfhr4 in the context of complement activation and immune regulation. In summary, Cfhr4 emerges as a pivotal player in orchestrating the delicate balance between initiation and regulation of complement activation, with activation mechanisms involving direct engagement of its functional domains and modulation of key signaling pathways crucial for immune surveillance and homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AEBSF hydrochloride | 30827-99-7 | sc-202041 sc-202041A sc-202041B sc-202041C sc-202041D sc-202041E | 50 mg 100 mg 5 g 10 g 25 g 100 g | $65.00 $122.00 $428.00 $851.00 $1873.00 $4994.00 | 33 | |
This compound inhibits protease activity, indirectly activating Cfhr4 by preventing excessive complement factor H cleavage. Elevated Cfhr4 levels regulate complement activation by maintaining balance in C3b binding, crucial for preventing diseases like atypical hemolytic-uremic syndrome. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin influences the NF-κB signaling pathway, indirectly activating Cfhr4. By modulating this pathway, it enhances complement activation regulation. This flavonoid demonstrates potential in regulating complement factor H-related 4, providing insights into its involvement in diseases like lupus nephritis. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG, a green tea polyphenol, indirectly activates Cfhr4 by suppressing the MAPK pathway. By influencing this pathway, it contributes to complement activation regulation, suggesting a potential role in preventing systemic lupus erythematosus and related conditions. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol influences the SIRT1 pathway, indirectly activating Cfhr4 by modulating the NAD+-dependent deacetylase. This modulation affects complement activation regulation, suggesting a potential role in managing diseases such as hemolytic-uremic syndrome. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 inhibits NF-κB, indirectly activating Cfhr4 by modulating the NF-κB signaling pathway. This interference affects complement activation regulation, providing insights into potential therapeutic strategies for diseases like atypical hemolytic-uremic syndrome. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23 inhibits NF-κB translocation, indirectly activating Cfhr4 by modulating the NF-κB signaling pathway. This interference influences complement activation regulation, suggesting a potential role in managing diseases such as eye disease. | ||||||
[4-[(4-Benzo[b]thien-2-yl-2-pyrimidinyl)amino]phenyl][4-(1-pyrrolidinyl)-1-piperidinyl]-methanone | 873225-46-8 | sc-503387 | 10 mg | $430.00 | ||
Inhibits PI3K, indirectly activating Cfhr4 by disrupting the PI3K/Akt pathway. This interference influences complement activation regulation, providing insights into potential therapeutic strategies for diseases like lupus nephritis. | ||||||
Caffeic Acid | 331-39-5 | sc-200499 sc-200499A | 1 g 5 g | $32.00 $62.00 | 1 | |
Caffeic acid influences the Nrf2 pathway, indirectly activating Cfhr4 by modulating Nrf2-mediated responses. This modulation affects complement activation regulation, suggesting a potential role in managing diseases such as hemolytic-uremic syndrome. | ||||||